Publications

Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.

Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.

The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. Goldhill, Aartjan J. W. te Velthuis, Robert A. Fletcher, Pinky Langat, Maria Zambon, Angie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.

Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.

Citation

BibTex format

@article{Moshe:2021,
author = {Moshe, M and Daunt, A and Flower, B and Simmons, B and Brown, JC and Frise, R and Penn, R and Kugathasan, R and Petersen, C and Stockmann, H and Ashby, D and Riley, S and Atchison, C and Taylor, GP and Satkunarajah, S and Naar, L and Klaber, R and Badhan, A and Rosadas, C and Marchesin, F and Fernandez, N and Sureda-Vives, M and Cheeseman, H and O'Hara, J and Shattock, R and Fontana, G and Pallett, SJC and Rayment, M and Jones, R and Moore, LSP and Ashrafian, H and Cherapanov, P and Tedder, R and McClure, M and Ward, H and Darzi, A and Cooke, GS and Barclay, WS and On, behalf of the REACT Study team},
journal = {BMJ: British Medical Journal},
pages = {1--8},
title = {SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study},
url = {https://www.bmj.com/content/372/bmj.n423},
volume = {372},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Objective: To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national COVID-19 seroprevalence programme (REACT2).Design: Laboratory sensitivity and specificity analyses were performed for seven LFIAs on a minimum of 200 sera from individuals with confirmed SARS-CoV-2 infection, and 500 pre-pandemic sera respectively. Three LFIAs were found to have a laboratory sensitivity superior to the finger-prick sensitivity of the LFIA currently used in REACT2 seroprevalence studies (84%). These LFIAs were then further evaluated through finger-prick testing on participants with confirmed previous SARS-CoV-2 infection. Two LFIAs (Surescreen, Panbio) were evaluated in clinics in June-July, 2020, and a third LFIA (AbC-19) in September, 2020. A Spike protein enzyme-linked immunoassay (S-ELISA) and hybrid double antigen binding assay (DABA) were used as laboratory reference standards.Setting: Laboratory analyses were performed at Imperial College, London and University facilities in London, UK. Research clinics for finger-prick sampling were run in two affiliated NHS trusts.Participants: Sensitivity analysis on sera were performed on 320 stored samples from previous participants in the REACT2 programme with confirmed previous SARS-CoV-2 infection. Specificity analysis was performed using 1000 pre-pandemic sera. 100 new participants with confirmed previous SARS-CoV-2 infection attended study clinics for finger-prick testing.Main outcome measures: The accuracy of LFIAs in detecting IgG antibodies to SARS-CoV-2 in comparison to two in-house ELISAs.Results: The sensitivity of seven new LFIAs using sera varied between 69% and 100% (vs S-ELISA/hybrid DABA). Specificity using sera varied between 99.6% and 100%.  Sensitivity on finger-prick testing for Panbio, Surescreen and AbC-19 was 77% (CI 61.4 to 88.2), 86% (CI 72.7 to 94.8) and 69% (CI 53.8 to 81.3) respectively vs S-ELISA/hybrid DABA. Sensitivity for sera from matched clinical samples performe
AU  - Moshe,M
AU  - Daunt,A
AU  - Flower,B
AU  - Simmons,B
AU  - Brown,JC
AU  - Frise,R
AU  - Penn,R
AU  - Kugathasan,R
AU  - Petersen,C
AU  - Stockmann,H
AU  - Ashby,D
AU  - Riley,S
AU  - Atchison,C
AU  - Taylor,GP
AU  - Satkunarajah,S
AU  - Naar,L
AU  - Klaber,R
AU  - Badhan,A
AU  - Rosadas,C
AU  - Marchesin,F
AU  - Fernandez,N
AU  - Sureda-Vives,M
AU  - Cheeseman,H
AU  - O'Hara,J
AU  - Shattock,R
AU  - Fontana,G
AU  - Pallett,SJC
AU  - Rayment,M
AU  - Jones,R
AU  - Moore,LSP
AU  - Ashrafian,H
AU  - Cherapanov,P
AU  - Tedder,R
AU  - McClure,M
AU  - Ward,H
AU  - Darzi,A
AU  - Cooke,GS
AU  - Barclay,WS
AU  - On,behalf of the REACT Study team
EP  - 8
PY  - 2021///
SN  - 0959-535X
SP  - 1
TI  - SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study
T2  - BMJ: British Medical Journal
UR  - https://www.bmj.com/content/372/bmj.n423
UR  - http://hdl.handle.net/10044/1/86108
VL  - 372
ER  -
Download